SOUTH SAN FRANCISCO, Calif., Sept. 08, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a
biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced upcoming
Trials in Progress poster presentations for its two lead product candidates, CX-072, a PD-L1 targeting Probody therapeutic and
CX-2009, a Probody-drug conjugate targeting CD166, at the European Society for Medical Oncology Annual Meeting from September 8-12
in Madrid, Spain.
Abstract Information:
Title: |
The
First-in-Human, Dose-Finding PROCLAIM-CX-072 Trial to Assess the Antitumor Activity and Tolerability of the Probody
Therapeutic CX-072 as Monotherapy and in Combination With Ipilimumab or Vemurafenib in Solid Advanced Tumors and Lymphomas |
Author: |
Valentina Boni, M.D., Ph.D., START
Madrid-CIOCC, Madrid, Spain |
Date: |
Monday, September 11, 2017 |
Time: |
1:15 p.m. – 2:15 p.m. |
Location: |
Hall 8 |
Abstract: |
423TiP |
About the PROCLAIM-CX-072 Trial:
The PROCLAIM-CX-072 (PRObody CLinical Assessment In
Man) study is designed to evaluate tolerability, and preliminary antitumor activity and translational biomarkers
of multiple doses of CX-072 as monotherapy or as combination therapy with ipilimumab or vemurafenib in patients with advanced,
unresectable solid tumors or lymphoma. This first-in-human, open-label, multicenter, dose-escalation, phase 1/2 study of
CX-072 includes 4 dose-escalation groups (monotherapy, Part A; 2 ipilimumab combination schedules, Parts B1 and B2; vemurafenib
combination, Part C), a stage testing biomarkers and efficacy in PD-L1+ tumors (Part A2), and a dose-expansion phase (Part D).
Abstract Information:
Title: |
PROCLAIM-CX-2009: A First-in-Human Trial to Evaluate CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid
Tumors |
Author: |
Javier Garcia-Corbacho M.D.,
Hospital Clinic Barcelona, Barcelona, Spain |
Date: |
Monday, September 11, 2017 |
Time: |
1:15 p.m. – 2:15 p.m. |
Location: |
Hall 8 |
Abstract: |
422TiP |
About the PROCLAIM-CX-2009 Trial:
The objectives of the ongoing PROCLAIM-CX-2009 (PRObody CLinical Assessment
In Man) module are to determine the maximum tolerated dose (MTD), recommended phase 2 dose
(RP2D), dose-limiting toxicities, and preliminary antitumor activity of CX-2009 as monotherapy in the following 7 selected tumor
types with high CD166 expression: breast carcinoma, castration-resistant prostate carcinoma (CRPC), cholangiocarcinoma, endometrial
carcinoma, epithelial ovarian carcinoma, head and neck squamous cell carcinoma (HNSCC), and non–small cell lung carcinoma
(NSCLC).
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of
Probody™ therapeutics. Probody therapeutics exploit unique conditions of the tumor microenvironment to more effectively localize
antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer
immunotherapies against clinically-validated targets, such as PD-L1 and first-in-class Probody drug conjugates against highly
attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to
their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations
with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen,
Inc. For more information, visit www.cytomx.com or follow us on Twitter.
Media Contact:
Spectrum
Christine Quern
cquern@spectrumscience.com
202-587-2588
Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973